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Abstract: Owing to their unique structural features, non-lamellar liquid crystalline nanoparticles
comprising cubosomes and hexosomes are attracting increasing attention as versatile investigative
drug carriers. Background: Depending on their physiochemical characteristics, drug molecules
on entrapment can modulate and reorganize structural features of cubosomes and hexosomes.
Therefore, it is important to assess the effect of guest molecules on broader biophysical characteristics
of non-lamellar liquid crystalline nanoparticles, since drug-induced architectural, morphological,
and size modifications can affect the biological performance of cubosomes and hexosomes. Methods:
We report on alterations in morphological, structural, and size characteristics of nanodispersions
composed from binary mixtures of glycerol monooleate and vitamin E on thymoquinone (a molecule
with wide therapeutic potentials) loading. Results: Thymoquinone loading was associated with
a slight increase in the mean hydrodynamic nanoparticle size and led to structural transitions from
an internal biphasic feature of coexisting inverse cubic Fd3m and hexagonal (H2) phases to an internal
inverse cubic Fd3m phase (micellar cubosomes) or an internal inverse micellar (L2) phase (emulsified
microemulsions, EMEs). We further report on the presence of “flower-like” vesicular populations
in both native and drug-loaded nanodispersions. Conclusions: These nanodispersions have the
potential to accommodate thymoquinone and may be considered as promising platforms for the
development of thymoquinone nanomedicines.
Keywords: drug encapsulation; inverse cubic Fd3m phase; inverse hexagonal phase; nanodispersions;
micellar cubosomes; nanoparticle tracking analysis; synchrotron small-angle scattering
1. Introduction
Nigella sativa, commonly known as black cumin, fennel flower, and kalonji, is an annual herbaceous
plant with a rich religious and historical background [1–3]. It belongs to the botanical Ranunculaceae
family and is used in the preparation of herbal medicines [1–7]. It is native to North Africa,
Southern Europe, and Southwest Asia, and is cultivated in India, Pakistan, and Middle Eastern
and Mediterranean countries [7]. Black cumin seeds and its extracted oil have been indicated for
potential treatment and prevention of a variety of conditions including bronchial asthma, eczema,
infectious diseases (e.g., influenza, dysentery), obesity, hypertension, gastrointestinal disorders,
and pain relief [1–7].
The therapeutic potentials of black cumin seeds are mainly attributed to thymoquinone (TQ), which is
the main active compound (30–48%) of the volatile (essential) oil of Nigella sativa [1–4,7,8]. TQ, 2-isopropyl-5-
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methylbenzo-1,4-quinone, is a quinone with relatively poor water solubility (0.549–0.740 g/L) [8,9]. Among its
pharmacological properties, TQ displays antioxidant, antihistamine, immunomodulatory, anti-inflammatory,
anti-microbial, and neuroprotective activities [2,5–7,10,11]. It was also reported that TQ is a potent anticancer
agent and has potential in the prevention and treatment of breast, colon, and ovarian cancers [4,9,10,12–14].
Despite its broad therapeutic potentials, there are major concerns and limitations (including
low solubility in water, poor bioavailability, poor membrane penetration capacity, and lack of
mechanistic understanding of the drug action) hindering the translational development of TQ-based
formulations [4,5,9,10]. Overcoming these limitations might be achieved through the rational design
of nanoparticulate formulations for TQ delivery [4,8,11,15–18]. Taking into account the current
interest in the development of nanocarriers for delivering TQ and other phytochemicals [8–11,15–21],
here we focus on non-lamellar liquid crystalline nanoparticles enveloping a biphasic feature of inverse
discontinuous cubic (I2) phase of the symmetry Fd3m phase coexisting with an inverse hexagonal
(H2) phase for TQ encapsulation. The unique structural properties of these nano-self-assemblies
and their analogues [22–41] render them particularly attractive for enhancing the solubilization
capacity of poorly water-soluble drugs and improving their delivery through different routes of
administration [23,26,27,29,36]. However, the structural features of this family of liquid crystalline
nanoparticles is highly sensitive to drug loading, and subsequently could affect its stability as well as
biological performance. Here, we examine the effect of TQ loading on the structural and morphological
features of non-lamellar liquid crystalline nanoparticles from a binary lipid mixture consisting of
glycerol monooleate (GMO), which is the most investigated lipid with non-lamellar liquid crystalline
phase forming propensity, and vitamin E (Vit E). These preparations were stabilized with d-α-tocopheryl
poly(ethylene glycol)2000 succinate (TPGS-PEG2000) and their characteristics were investigated through
a pan-integrated approach involving synchrotron small angle X-ray scattering (SAXS), nanoparticle
tracking analysis (NTA), and cryo-transmission electron microscopy (Cryo-TEM). We further report on
TQ encapsulation efficiency and the effect of ageing on the mean nanoparticles sizes within 30 days of
post-preparation of structurally optimized samples.
2. Results and Discussion
2.1. Biophysical Characteristics of Drug-Free GMO/Vit E Nano-Self-Assemblies
Figure 1 shows the molecular formulas of TQ, TPGS-PEG2000, and the lipid constituents of
the nanodispersions. Composition and main biophysical characteristics of TQ-free and TQ-loaded
nanodispersions are presented in Tables 1 and 2. The interior organization of GMO/Vit E (weight ratios
of 70:30 and 60:40) nano-self-assemblies stabilized with different concentrations of TPGS-PEG2000
(0.75–1.5 wt%) was studied by synchrotron SAXS. With both lipid compositions, the SAXS patterns
for the TPGS-PEG2000-stabilized nanodispersions (Figure 2A,B) indicated the formation of species
enveloping an internal biphasic feature of coexisting inverse hexagonal (H2) phase and inverse
discontinuous (micellar) cubic phase of the symmetry Fd3m. The identification of these phases
presented in Figure 2A,B was based on the detection of the first three characteristic peaks for the former
phase (reflections marked with blue solid arrows: (100), (110), and (200)) and at least nine characteristic
Bragg peaks (reflections marked with black dash arrows: (111), (220), (311), (222), (400), (331), (422),
(511), (333), (440)) for the latter phase. The inverse cubic Fd3m (Q227) phase is a three-dimensional
(3D) nanostructure enveloping quasi-spherical micelles with two different sizes and is the most
identified micellar cubic phase in lipid systems [38,42–47], and previously observed between the
inverse hexagonal (H2) and micellar (L2) phases in both dispersed and non-dispersed systems based
on binary mixtures of unsaturated monoglyceride (e.g., GMO, monolinolein, and monoelaidin) and
solubilized oil (e.g., Vit E, oleic acid, tetradecane, and elaidic acid) [38,44–46].
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Figure 1. The molecular formulas of glycerol monooleate (GMO), vitamin E (Vit E), D-α-tocopheryl 
poly(ethylene glycol)2000 (TPGS-mPEG; m: 2000), and thymoquinone (TQ). 
Table 1. Composition and biophysical characteristics of engineered drug-free and TQ-loaded TPGS-
PEG2000-stabilized GMO/Vit E nanodispersions. Synchrotron small angle X-ray scattering (SAXS) 
experiments were performed at 37 °C. 
Sample  
Lipids  
Stabilizer (wt%) TQ (mg/mL) Space Group Lattice Parameter (nm) 
(GMO/Vit E Ratio) 
1 70:30 0.75 0 
Fd3m 
H2 
17.45 
5.45 
2 70:30 1.0 0 
Fd3m 
Fd3ma 
H2 
17.45 
18.60 
5.50 
3 70:30 1.5 0 
Fd3m 
H2 
17.34 
6.02 
4 60:40 0.75 - 
Fd3m 
H2 
16.20 
5.64 
5 60:40 1.0 - 
Fd3m 
H2 
16.20 
5.64 
6 60:40 1.5 - 
Fd3m 
H2 
16.20 
5.64 
7 70:30 1.5 2.5 Fd3m 16.81 
8 70:30 1.5 5 L2b 4.95 
9 70:30 1.5 7.5 L2b 4.95 
10 70:30 1.5 10 L2b 4.69 
11 60:40 0.75 5 L2b 4.55 
12 60:40 1.0 5 L2b 4.53 
13 60:40 1.5 5 L2b 4.53 
a The lattice parameter of the coexisting second cubic Fd3m phase that was identified based on the 
detection of four weak reflections (marked with asterisk in Figure 2A). b The characteristic distance of 
the inverse micellar (L2) phase.  
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Table 1. Composition and biophysical characteristics of engineered drug-free and TQ-loaded TPGS-
PEG2000-stabilized GMO/Vit E nanodispersions. Synchrotron small angle X-ray scattering (SAXS)
experiments were performed at 37 ◦C.
Sample
Lipids
Stabilizer (wt%) TQ (mg/mL) Space Group Lattice Parameter (nm)
(GMO/Vit E Ratio)
1 70:30 0.75 0 Fd3mH2
17.45
5.45
2 70:30 1.0 0
Fd3m
Fd3ma
H2
17.45
18.60
5.50
3 70:30 1.5 0 Fd3mH2
17.34
6.02
4 60:40 0.75 - Fd3mH2
16.20
5.64
5 60:40 1.0 - Fd3mH2
16.20
5.64
6 60:40 1.5 - Fd3mH2
16.20
5.64
7 70:30 1.5 2.5 Fd3m 16.81
8 70:30 1.5 5 L2b 4.95
9 70:30 1.5 7.5 L2b 4.95
10 70:30 1.5 10 L2b 4.69
11 60:40 0.75 5 L2b 4.55
12 60:40 1.0 5 L2b 4.53
13 60:40 1.5 5 L2b 4.53
a The lattice parameter of the coexisting second cubic Fd3m phase that was identified based on the detection of four
weak reflections (marked with asterisk in Figure 2A). b The characteristic distance of the inverse micell r (L2) phas .
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Table 2. Hydrodynamic size characteristics and encapsulation efficiency (EE) of selected TQ-free and
TQ-loaded GMO/Vit E) nanodispersions a.
Sample
Lipids Stabilizer
(wt%)
TQ
(mg/mL)
Mean Particle Size ± SD
(nm)
Mode ± SD
(nm)
EE ± SD
(%)
EE ± SD
(%)
(GMO/Vit E Ratio) Preparation Day 5 Days
1 70:30 1.5 0 145 ± 49 126 ± 11
4 60:40 0.75 0 119 ± 49 95 ± 3
6 60:40 1.5 0 141 ± 53 131 ± 3
8 70:30 1.5 5 160 ± 65 134 ± 7 - -
11 60:40 0.75 5 127 ± 43 118 ± 3 98.8 ± 0.09 97.6 ± 0.11
13 60:40 1.5 5 168 ± 67 136 ± 1 98.9 ± 0.10 97.9 ± 0.09
14 70:30 1.5 7.5 - - 99.4 ± 0.05 -
a Nanoparticle tracking analysis (NTA) measurements were conducted on selected TQ-loaded nanodispersions
prepared at TQ concentration of 5 mg/mL. The EE of TQ in the selected nanodispersions was determined in the
preparation day (day 0) and after 5 days of preparation.
Notably, increasing TPGS-PEG2000 concentration at both lipid compositions, particularly at
GMO/Vit E ratio of 60:40 (Figure 2B), did not have a significant influence on the lattice parameters
of both coexisting H2 and cubic Fd3m phases (Table 1). This is most likely attributed to the tendency
of TPGS-PEG2000 to form micelles and vesicles as previously reported [48,49]. At GMO/Vit E
ratio of 70:30 (Figure 2A), the results showed a slight increase in the lattice parameter of the
coexisting H2 phase on increasing TPGS-PEG2000 concentration from 0.75 to 1.5 wt%. Furthermore,
the SAXS pattern showed traces of an additional cubic Fd3m phase with Bragg peaks (marked
with asterisks) having a lattice parameter of approximately 18.60 nm at 1.0 wt% TPGS-PEG2000
(Figure 2A, dark blue SAXS pattern). These structural alterations are most likely attributed to
the accommodation of relatively small amounts of TPGS-PEG2000 in the internal nanostructure of
GMO/Vit E nanoparticles leading to a slight enlargement of hydrophilic domains. These observations
are in line with previous studies showing that the incorporation of PEGylated stabilizers into
hydrophilic domains of lipid nanodispersions can induce significant structural alterations and
phase transitions [24,25,50,51]. For instance, we recently reported on the significant influence
of three different poly(ethylene glycol)-grafted 1,2-distearoyl-sn-glycero-3-phosphoethanolamines
(DSPE-mPEG), namely DSPE-PEG350, DSPE-PEG750, and DSPE-PEG2000, on the enlargement of
internal hydrophilic water channels in bicontinuous cubic Pn3m and Im3m phases of cubosomes based
on phytantriol [51].
Depending on the lipid composition, the stabilizer type, and its concentration, non-lamellar
liquid crystalline nanodispersions display a typically heterogeneous environment of coexisting
morphologies [24,25,32,52–56]. For instance, Pluronic F127-stabilized cubosomes and hexosomes
typically coexist with vesicles [22,54,57,58]. Accordingly, we used cryo-TEM to gain further insight
into the morphological features of the non-lamellar liquid crystalline nanoparticles and their possible
coexistence with vesicles, micelles, or other species. For a selected nanodispersion prepared at GMO/Vit
E weight ratio of 70:30 and TPGS-PEG2000 concentration of 1.5 wt%, the recorded cryo-TEM images
displayed species with diameters in the range of a few tens to a few hundred nanometers (Figure 3A–D).
Furthermore, the images show the presence of “flower-like” vesicles (marked with red dash arrows)
covering the non-lamellar liquid crystalline nanoparticles (marked with white solid arrows) that have
sizes in the range of 130–270 nm. These morphologies were not observed in cubosomes, hexosomes,
and other related nano-self-assemblies stabilized with Pluronic F127 [45,52–54,57,59]. Based on SAXS
findings (Figure 2A), these visible non-lamellar liquid crystalline nanoparticles are most likely micellar
cubosomes with an internal cubic Fd3m phase, since there was no indication (Figure 3) on the formation
of hexosomes with their typical morphological features of hexagons and curved striations [60].
NTA was used to gain insight into the hydrodynamic size and size distribution of selected GMO/Vit
E nanodispersions. NTA results showed that the mean hydrodynamic diameters and modes for the
two nanodispersions prepared at GMO/Vit E weight ratio of 60:40 (control samples 4 and 6, Table 2) were
increased from 119± 49 and 95± 3 nm to 141± 53 and 131± 3 nm, respectively on increasing TPGS-PEG2000
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concentration from 0.75 to 1.5 wt%. The reason for such a size increase is unclear, but this may be attributed
to the occurrence of a higher fraction of coexisting relatively large vesicles with the non-lamellar liquid
crystalline nanoparticles on increasing TPGS-PEG2000 concentration. At TPGS-PEG2000 concentration of
1.5 wt%, an increase in GMO/Vit E weight ratio to 70:30 (sample 1, Table 2) did not induce a significant
change in the mean nanoparticle size and mode.
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Figure 2. Effects of stabilizer (TPGS-PE 2000) and TQ loading on the internal na ostructure of
GMO/Vit E nanoparticles. SAXS patterns a 37 ◦C for (A,B) TQ-free and (C,D) TQ-loaded GMO/Vit E
nanodispersions contained a constant total lipid (GMO/Vit E binary mixture) concent ation of 5.0 wt%.
These samples w re prepared at two differen GMO/Vit E weight ra ios: (A,C) 70:30 and (B,D) 60:40.
In (A), (B), and (D), the samples were stabilized with TPGS-PEG2000 at ree different concentrations of
0.75, 1.0, and 1.5 wt%; whereas those in panel (C) ere stabilized using the same stabilizer at a co stant
concentration of 1.5 wt%. The Bragg peaks are represented with black dash arrows an blue solid
arrows for the corresponding Miller indic s f the cubic Fd3m and H2 phases, respectively. In (A),
the detected characteristic Bragg peaks for the second coexisting cubic Fd3m phase at TPGS-PEG2000
content of 1.0 wt% are marked with an asterisk. In all panels, the intensities were shifted by a constant
arbitrary factor for better visibility.
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loaded samples prepared at GMO/Vit E weight ratio of 70:30 and stabilized with TPGS-PEG2000 at a 
concentration of 1.5 wt% (samples 3 and 7, respectively in Table 1). These GMO/Vit E nanodispersions 
were prepared at a total lipid concentration of 5.0 wt% and contained TQ at concentrations of 0 
(sample 3) and 2.50 mg/mL (sample 7), respectively. In these images, the visible non-lamellar liquid 
crystalline nanoparticles are marked with solid white arrows, whereas the adsorbed flower-like 
vesicular structures on the nanoparticles’ surfaces are marked with red dash arrows. In (A), (B), and 
(D), the dark spot indicating the formation of an ice crystal on the microscope grid is marked with a 
yellow asterisk. In all panels, the coexisting small nano-objects (most likely vesicles) are marked with 
green arrowheads; whereas the visible larger deformed and elongated vesicular structures are 
marked with solid dash arrows. In all images and enlarged areas, the scale bar is 100 nm. 
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Figure 3. Cryo-transmission electron microscopy (TEM) images of (A–D) TQ-free and (E–G) TQ-loaded
samples prepared at GMO/Vit E weight ratio of 70:30 and stabilized with TPGS-PEG2000 at a concentration
of 1.5 wt% (samples 3 and 7, respectively in Table 1). These GMO/Vit E nanodispersions were prepared at
a total lipid concentration of 5.0 wt% and contained TQ at concentrations of 0 (sample 3) and 2.50 mg/mL
(sa ple 7), respectively. In these i ages, the visible non-lamellar liquid crystalline nanoparticles are marked
with solid white arrows, whereas the adsorbed flower-like vesicular structures on the nanoparticles’ surfaces
are marked with red dash arrows. In (A), (B), and (D), the dark spot indicating the formation of an ice crystal
on the microscope grid is marked with a yell w asterisk. In all pan ls, the coexisting small nano-objects
(most likely vesicles) are marked with green arrowheads; wher as the visible larger deformed and elongated
vesicul structure are marked with olid dash arrows. In all images and enlarged area , the scale bar
is 100 nm.
2.2. Effect of TQ Loading on Biophysical Characteristics of GMO/Vit E Nano-Self-Assemblies
We investigated the effect of TQ loading on biophysical characteristics of selected TPGS-PEG2000-
stabilized GMO/Vit E nanodispersions (Table 1, Figure 2C,D). Loading TQ at 2.5 mg/mL led to
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a structural transition from an internal biphasic cubic Fd3m/H2 feature (vivid orange SAXS pattern,
Figure 2C) having lattice parameters of 17.34 and 6.02 nm, respectively, to micellar cubosomes
with an internal neat cubic Fd3m phase having a lattice parameter of 16.81 nm (red SAXS pattern,
Figure 2C). On further increasing TQ concentration (5–10 mg/mL), a structural transition from
an internal cubic Fd3m phase (micellar cubosomes) to an internal L2 phase (formation of emulsified
microemulsions, EMEs) was observed. The latter phase was characterized by the appearance of a single
broad peak with corresponding q values of 1.27, 1.27, and 1.34 nm−1, respectively, with increasing
TQ concentration from 5 to 7.5, and 10 mg/mL (Figure 2C). This change in q was associated with
a slight decrease in the characteristic distance of the internal L2 phase from 4.95 to 4.69 nm (Table 1).
At GMO/Vit E ratio of 60:40 and the following three different concentrations of TPGS-PEG2000: 0.75,
1.0, and 1.5 wt% (Table 1 and Figure 2D), a similar phase transition was detected from an internal
biphasic cubic Fd3m/H2 feature to an internal L2 phase on loading TQ at a constant concentration of
5 mg/mL. It was evident that TQ has a significant effect on the internal nanostructure of GMO/Vit
E nano-self-assemblies, with almost no effect of the stabilizer in the investigated concentration
range as the characteristic distance of the internal L2 phase was similar at the three employed
TPGS-PEG2000 concentrations. This observation might be attributed to preferential formation of
coexisting micelles and vesicles on increasing TPGS-PEG2000 concentration as discussed above.
These detected cubic Fd3m/H2-L2 phase transitions on increasing TQ concentration are consistent with
previous reports [22,31,43,45,54,61–64] on the influence of solubilizing a hydrophobic additive such as
medium chain triglycerides and oleic acid on the structural features of non-lamellar liquid crystalline
phases (in both dispersed and bulk (non-dispersed) states). It was reported that the localization of such
guest molecules in the hydrophobic (lipidic) domains of the internal non-lamellar liquid crystalline
phase leads in a concentration-dependent manner to the following typical colloidal transformations:
cubosomes with an internal bicontinuous cubic phase, via hexosomes with an internal H2 phase,
to micellar cubosomes and EMEs with internal cubic Fd3m and L2 phases, respectively [43,45,54,64].
A number of plausible reasons might account for this sequential phase transition in the nanoparticles’
interiors [42–44,54,65], such as associated change with water quantity (dehydration effect), increase
in the effective volume of the acyl chains of the main surfactant-like lipid constituents, and release
of packing frustrations by filling out the interstitial regions of the hydrophobic domains of the
internal nanostructure.
Cryo-TEM was further employed to shed light on the effect of loading TQ on morphological
characteristics of selected nanodispersions. In Figure 3E–G, the cryo-TEM images from TQ encapsulated
(2.5 mg/mL) GMO/Vit E nanodispersion (weight ratio 70:30; 1.5 wt% TPGS-PEG2000) displayed
morphologies with size diameters in the range of a few tens to a few hundred nanometers and similar
to those detected in the corresponding TQ-free nanodispersion (Figure 3A–D). The nature of the
cubic Fd3m phase [52,66], however, creates a technical challenge in visualizing the internal structure
of TQ-free and TQ-loaded nanodispersions by cryo-TEM (Figure 3), since this phase is composed
of two different closely packed quasi-spherical reversed micelles with relatively low amounts of
“solubilized” water, and a reduced contrast between the lipid and water domains compared with
nanoparticles with internal H2 and V2 phases in hexosomes and cubosomes, respectively that generally
have larger water domains [45,52,54,66]. The images further show the presence of coexisting small
spherical morphologies (marked with green arrowheads) in a size range of 15–55 nm (Figure 3).
These small aggregates are most likely representing coexisting vesicles. Considering the tendency
of TPGS-PEG2000 to form normal micelles (L1 phase) [48,49], we do not exclude the coexistence of
micelles in these nanodispersions. In addition to these, other relatively larger deformed and elongated
vesicular structures (marked with black dash arrows) were also visible in cryo-TEM images (Figure 3).
For nanodispersions prepared by employing the same TPGS-PEG2000 concentration, it was
evident from NTA findings that loading TQ at a concentration of 5 mg/mL was associated with
a slight increase in the mean nanoparticle hydrodynamic size and mode (Table 2). This is most
likely attributed to the observed TQ-mediated structural changes in GMO/Vit E nano-self-assemblies
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(Figure 2C). Previous investigations have also confirmed an increase in the mean nanoparticle size on
TQ encapsulation in other lipidic and polymeric-based nanocarriers [11,67].
Finally, we also assessed the effect of ageing on the nanoparticle size at ambient temperature within
a month of preparation. The results demonstrated no significant changes in the mean nanoparticle size,
regardless of lipid composition, stabilizer or drug concentration (Figure 4). GMO/Vit E nanodispersions
were also visually inspected and found to be colloidally stable for at least three months after preparation.
2.3. Encapsulation Efficiency of TQ-Loaded GMO/Vit E Nano-Self-Assemblies
The encapsulation efficiency (EE) of TQ was tested on three selected GMO/Vit E nanodispersions
prepared at GMO/Vit E weight ratios of 70:30 and 60:40 and found to be 99.0 wt% in the preparation
day (Table 2). This observation was consistent with previous reports on TQ encapsulation in Tween
80-stabilized lipid carriers based on hydrogenated palm oil, lecithin, and olive oil, and liposomes based
on 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) [11,17]. In line with previous investigations
on the EE of poorly water-soluble drugs [11,17,68], the obtained high EE in this study is most likely
attributed to high lipophilicity of TQ and its preferential localization within the hydrophobic domains
of the internal nanostructures of these GMO/Vit E nano-self-assemblies. The EE of TQ was also
determined for two selected samples at GMO/Vit E weight ratio of 60:40 (samples 11 and 13 in Table 2)
after five days of preparation, and the results indicated a marginal decrease in the EE (Table 2).
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E nanodispersions. All nanodispersions were prepared at a constant GMO/Vit E ratio of 60:40 and
total lipid (GMO plus Vit E) concentration of 5.0 wt%. The TQ-free (control) samples were stabilized
with TPGS-PEG2000 at the following concentrations: 0.75 wt% (sample 4, red bars), 1.0 wt% (sample 5,
green bars), 1.5 wt% (sample 6, dark blue bars). The two selected TQ-loaded samples were prepared at
TQ concentration of 5 mg/mL and stabilized by TPGS-PEG2000 at 0.75 wt% (sample 11, orange bars)
and 1.5 wt% (sample 13, olive green bars). The samples were analyzed at room temperature at the
following time points: 0 (preparation day), 10, 20, and 30 days.
3. Materials and Methods
3.1. Materials
Glycerol monooleate (GMO, product name: RIKEMAL-XO-100) with a purity ≥ 90% was obtained
from Riken Vita i Co. (Tokyo, Japan). Vitamin E (Vit E) with a purity ≥ 96% was purchased from
Sigma Aldrich (Helsinki, Finland). d-α-tocopheryl poly (ethyle e glycol)2000 succinate (TPGS-PEG2000)
was purchased from Isochem (Vert-Le-P tit, France). Thymoquin ne (TQ, purity≥ 99%) was purchased
from Sarchem Laboratories, Inc. (Farmingdale, NJ, USA). Phosphate buffered saline (PBS) tablets
at pH 7.4 were purchased from Sigm Aldrich (Poole, UK). For p eparing the 0.01 M PBS buffer,
Milli-Q water was collected from Millipore Direct-Q3 UV syste (Bille i a, MA, USA). Ethanol with
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a purity ≥96% was obtained from Merck (Darmstadt, Germany). All ingredients were used without
further purification.
3.2. Preparation of Thymoquinone-Free and Thymoquinone-Loaded GMO/Vit E Nanodispersions
The TQ-free and TQ-loaded nanodispersions were prepared using binary GMO/Vit E mixtures
at the following four GMO/Vit E weight ratios: 90:10, 70:30, 60:40, and 50:50. These nanodispersions
were prepared at different TQ concentrations ranging from 0 to 7.5 mg/mL, and the total lipid (binary
GMO/Vit E mixture) concentration was kept constant at 5.0 wt%. GMO was first melted at ~40 ◦C
and weighed into a glass vial followed by the addition of Vit E and vortexing to obtain a clear lipid
binary solution. To prepare TQ-loaded nanodispersions, appropriate amounts of TQ were dissolved
in the molten binary lipid GMO/Vit E mixtures by a gentle vortexing. Preheated TPGS-PEG2000 at
concentrations in the range of 0.75–1.5 wt% and 60 ◦C were then added, and the obtained clear lipid
solutions were gently vortexed in excess of 0.01 M phosphate buffer (pH 7.4). These samples were then
subjected to ultrasonication by using the ultrasonic processor Qsonica 500 (Qsonica LLC, Newtown,
CT, USA) for 5 min in pulse mode (5 s pulses interrupted by 2 s breaks) at 25% of its maximum power
(500 W). Based on visual inspections, these produced GMO/Vit E nanodispersions were found to be
colloidally stable for at least three months of post-preparation at room temperature.
3.3. Size Characterization of GMO/Vit E Nanodispersions
Size characterization of the nanoparticles in six selected TQ-free and TQ-loaded GMO/Vit E
nanodispersions was conducted as recently described in [29] by using NanoSight NS300 mounted
with a 405 nm laser and a microscope (Malvern Panalytical Ltd., Worcestershire, UK). Briefly, the size
measurements were performed in triplicate at room temperature, and the data represent the obtained
average values of these runs. Prior to measurements, the samples were diluted in filtered PBS
buffer (pH 7.4) to reach nanoparticle concentration between 108 and 109 nanoparticles/mL. In these
measurements, the recorded videos were analyzed using Malvern software (NTA 3.2 Dev Build 3.2.16,
Malvern Panalytical Ltd., Worcestershire, UK).
3.4. Cryo-Transmission Electron Microscopy (Cryo-TEM)
The morphological characterization of the selected TQ-free and TQ-loaded nanodispersions was
performed, as described in our recent reports [34,35]. Briefly, 3–4 µL of the nanodispersion was
applied on a hydrophilized lacey carbon 300 mesh copper grid (Ted Pella Inc., Redding, CA, USA).
The observations were done with Tecnai G2 20 transmission electron microscope (FEI, Eindhoven,
Holland) at a voltage of 200 kV under a low-dose rate (~5 e/Å2s). Images were then recorded using
a FEI Eagle camera 4k × 4k at a nominal magnification of 69,000× resulting in a final image sampling
of 0.22 nm/pixel.
3.5. Synchrotron Small-Angle X-ray Scattering (SAXS)
The experiments were performed on the I22 beamline at the Diamond Light Source synchrotron
at Harwell Campus (Didcot, UK). An X-ray beam having a wavelength of 0.9998 Å at X-ray energy of
12.4 KeV was used, with a sample-to-detector distance of 3563.3 mm, and a beam size of 120 × 370 µm2.
The 2D SAXS patterns were acquired using a Pilatus 2M from Dectris Ltd. (Baden, Switzerland).
Silver behenate (CH3-(CH2)20-COOAg with a d-spacing value of 58.38 Å) was used as a standard to
calibrate the angular scale of the measured intensity. In our investigations, 1 mm diameter quartz
capillaries (sample holders) were used and the measurements were performed by sealing the samples
in the thin-walled glass capillaries at 37 ◦C with an exposure time of 5 s per frame with 2 s delay
between 3 frames. The q range was 0.10 to 6.0 nm−1 (q = 4pi sin θ/λ, where λ is the wavelength and 2θ
is the scattering angle). The software, Dawn version 2.7, available with 2D data reduction pipeline
perspective was used for SAXS data reduction. After subtracting the background scattering using PBS
buffer, all Bragg peaks were fitted by Lorentzian distributions. The lattice parameters of the internal
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inverse discontinuous cubic Fd3m and hexagonal (H2) phases of GMO/Vit E nanoparticles were derived
from the SAXS diffraction patterns. We note that in each respective phase regime, only the strongest
reflections were considered for calculating the corresponding lattice parameters. The scattering profile
of the inverse micellar solution (the L2 phase) was characterized by the appearance of a single broad
peak, which was fitted for calculating its characteristic distance, d = 2pi/q.
3.6. Encapsulation Efficiency
The encapsulation efficiency (EE) of TQ was determined by using the following indirect method:
the free (un-encapsulated) TQ was isolated from the nanodispersion by centrifugation (9600 rcf) for
10 min using a microcentrifuge (VWRTM 1207 Galaxy 7D® Centrifuge, Radnor, PA, USA) and then its
concentration was determined, as described in the previous report of Salmani et al. [69], at a wavelength
of 257 nm by using Cary 60 UV-VIS spectrophotometer (Agilent Technologies, Santa Clara, CA, USA).
For TQ quantification, a calibration curve was prepared by dissolving the drug in ethanol at different
concentrations in the range of 0.5–10 µg/mL.
TQ encapsulation efficiency (EE) was calculated using the following equation [36]:
EE (%) =
Ctotal −C f ree
Ctotal
× 100% (1)
where Cfree refers to the concentration of un-encapsulated TQ as determined by UV-VIS spectrophotometer;
whereas Ctotal is the initial concentration of TQ in the nanodisperison.
4. Concluding Remarks
Non-lamellar liquid crystalline nanoparticles are attracting increasing interest for drug delivery
applications. For evaluating the potential pharmaceutical use of these nano-self-assemblies, it is
important to gain insight into the influence of lipid composition and drug loading on their structural
features, size, and morphological characteristics. The present study demonstrated that TQ in
a concentration-dependent manner dramatically alters the internal nanostructure as well as the
morphological features of TPGS-PEG2000-stabilized GMO/Vit E nanoparticles. Furthermore, cryo-TEM
observations demonstrated that native as well as TQ-loaded GMO/Vit E nanodispersions coexist
with vesicles, relatively small spherical nano-objects, and vesicular nanostructures with “flower-like”
features. More specifically, the ‘lamellar petals’ morphologies were covering the outer surfaces of
nanoparticles with a dense core of non-lamellar liquid crystalline structures.
Taking into account the important role of nanoparticle shape and surface characteristics on
modulating interactions with biological fluids, enzymes (e.g., lipases), and cells [70–73], future studies
are necessary to assess the performance of TQ-loaded non-lamellar liquid crystalline nanoparticles in
appropriate biological environments and animal models, and evaluate their drug release properties.
This could lead to design optimization and formulation validation with necessary regulatory attributes
for reproducible pharmaceutical development.
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